Spots Global Cancer Trial Database for previously treated
Every month we try and update this database with for previously treated cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma | NCT01302496 | Malignant Melan... Malignant Melan... | TriMix-DC and i... | 18 Years - | Universitair Ziekenhuis Brussel | |
| MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | NCT02592577 | Non-Small Cell ... Carcinoma | Autologous Gene... | 18 Years - | Adaptimmune | |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | NCT01350401 | Melanoma | Autologous gene... | 18 Years - | Adaptimmune | |
| PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib | NCT00548093 | Carcinoma, Non ... | PF-00299804 PF-00299804 | 18 Years - 99 Years | Pfizer | |
| The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer | NCT00345059 | Advanced Non-Sm... | docetaxel vinorelbine gemcitabine capecitabine | - 75 Years | National Cancer Institute, Naples | |
| Cetuximab Rechallenge Study | NCT01832467 | Metastatic Colo... | cetuximab-conta... | 18 Years - | Chinese University of Hong Kong | |
| Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer | NCT02301962 | Cancer | Panitumumab | 18 Years - | Dr. Reddy's Laboratories Limited | |
| AFPᶜ³³²T in Advanced HCC | NCT03132792 | Hepatocellular ... AFP Expressing ... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | NCT01350401 | Melanoma | Autologous gene... | 18 Years - | Adaptimmune | |
| AFPᶜ³³²T in Advanced HCC | NCT03132792 | Hepatocellular ... AFP Expressing ... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Safety and Tolerability of Intravenous Administration of ICVB-1042 | NCT05904236 | Patients With A... | Treatment with ... | 18 Years - | IconOVir Bio | |
| A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma | NCT01343043 | Neoplasms | NY-ESO-1(c259)T... Fludarabine Cyclophosphamid... | 4 Years - | GlaxoSmithKline | |
| Safety and Tolerability of Intravenous Administration of ICVB-1042 | NCT05904236 | Patients With A... | Treatment with ... | 18 Years - | IconOVir Bio | |
| A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma | NCT01343043 | Neoplasms | NY-ESO-1(c259)T... Fludarabine Cyclophosphamid... | 4 Years - | GlaxoSmithKline | |
| A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer | NCT00697060 | Carcinoma, Non-... | Imexon + doceta... | 18 Years - | AmpliMed Corporation | |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | NCT01350401 | Melanoma | Autologous gene... | 18 Years - | Adaptimmune | |
| Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma | NCT01302496 | Malignant Melan... Malignant Melan... | TriMix-DC and i... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO | NCT01465802 | Non Small Cell ... | Dacomitinib Dacomitinib Doxycycline Probiotic Alclometasone c... | 18 Years - | Pfizer | |
| RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA | NCT01497808 | Metastatic Mela... | Ipilimumab Stereotactic Bo... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor | NCT03132922 | Urinary Bladder... Melanoma Head and Neck C... Ovarian Cancer Non-Small Cell ... Esophageal Canc... Gastric Cancer Synovial Sarcom... Myxoid Round Ce... Gastroesophagea... | Autologous gene... Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01199575 | Chronic Lymphoc... CLL | Revlimid Rituximab | 18 Years - | University of California, San Diego | |
| Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling | NCT03760952 | Refractory Canc... Recurrent Cance... Adult Solid Tum... Neoplasms | 18 Years - | Immatics US, Inc. | ||
| Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01199575 | Chronic Lymphoc... CLL | Revlimid Rituximab | 18 Years - | University of California, San Diego | |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer | NCT01915472 | Metastatic Colo... | IMMU 130 | 18 Years - | Gilead Sciences | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor | NCT03132922 | Urinary Bladder... Melanoma Head and Neck C... Ovarian Cancer Non-Small Cell ... Esophageal Canc... Gastric Cancer Synovial Sarcom... Myxoid Round Ce... Gastroesophagea... | Autologous gene... Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib | NCT00548093 | Carcinoma, Non ... | PF-00299804 PF-00299804 | 18 Years - 99 Years | Pfizer | |
| The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer | NCT00345059 | Advanced Non-Sm... | docetaxel vinorelbine gemcitabine capecitabine | - 75 Years | National Cancer Institute, Naples |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
